Illumina Inc (NASDAQ:ILMN)., a leading player in the genomic sequencing industry, finds itself at a critical juncture as it navigates a shifting competitive landscape and global economic challenges.
The company shared pilot data about its Constellation tech and released 5-Base, a product for jointly analyzing genetic and epigenetic data.
SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic ...
Unlike conventional methylation conversion technologies, Illumina's proprietary conversion chemistry selectively converts methylated cytosine to thymine. This selective conversion of methylated ...
Illumina and Regeneron are taking stakes in health data company Truveta to help fund research that may dwarf the efforts of the National Institutes of Health’s All of Us million-person program and ...
Illumina is launching a new informatics and artificial intelligence software business aimed at drug developers, with the goal of digesting large-scale DNA sequencing and multi-omics data. The ...
SAVANA uses a machine learning algorithm to identify cancer-specific structural variations and copy number aberrations in long-read DNA sequencing data. The complex structure of cancer genomes means ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback